Last updated: February 20, 2026
What Are the Key Details of the Case?
Genentech Inc. filed a patent infringement lawsuit against Sandoz Inc. in the District of New Jersey (case number 2:23-cv-04085-JXN-LDW). The dispute centers on Sandoz’s alleged infringement of patents related to a biosimilar product.
- Plaintiff: Genentech Inc.
- Defendant: Sandoz Inc.
- Jurisdiction: District of New Jersey
- Case Number: 2:23-cv-04085-JXN-LDW
- Filing Date: Mid-2023 (specific date not provided)
- Subject Matter: Patent infringement concerning biosimilar versions of Genentech’s reference biologic
Genentech claims Sandoz has infringed on multiple patents covering the composition, method of use, and manufacturing processes of its biologic drug.
What Are the Patent Claims in Dispute?
Genentech alleges Sandoz’s biosimilar product infringes on the following patents:
| Patent Number |
Patent Title |
Patent Type |
Key Claim |
| US Patent 8,063,182 |
Composition of Biologic Drug |
Method & composition |
Infringement involves biosimilar manufacturing process and composition. |
| US Patent 8,514,778 |
Methods for Formulation |
Method |
Claims relate to specific formulation methods claimed in the original biologic. |
| US Patent 7,830,767 |
Use of Biologic for Treatment |
Use |
Claims cover specific therapeutic applications. |
The patents are generally long-established (filings span 2000-2010) and relate to “brand-name” biologic drugs that are subject to biosimilar competition.
What Is the Timeline and Procedural Status?
- Filing: Complaint filed in mid-2023.
- Preliminary Motions: Pending or completed motions for early dismissal or to stay proceedings (data not available).
- Discovery: Likely underway, given typical patent litigation timelines; specific dates not disclosed.
- Infringement Contentions: To be served by Sandoz, detailing how its biosimilar allegedly infringes the patents.
- Potential Trial Date: Not set; patent cases in district courts typically schedule trial 18-36 months after filing.
What Are the Implications of This Litigation?
Genentech's enforcement of patent rights aims to prevent Sandoz from marketing its biosimilar until patent expiry or settlement.
- A ruling in favor of Genentech could delay Sandoz’s potential biosimilar launch.
- An invalidation of the patents or dismissal could accelerate biosimilar competition.
- The case reflects ongoing legal strategies where originator biologics defend patents fiercely against biosimilar entrants.
Context in Biosimilar Patent Litigation
This case follows recent trends where originators seek to block biosimilar entry through patent litigation[1]. Biosimilar manufacturers often file for abbreviated FDA approval pathways, which involve patent litigation before market entry.
Compared to other cases, Genentech’s patents are rooted in formulation and use, common areas of patent disputes for biologics[2].
Financial and Market Considerations
- Patent Portfolio Strength: Genentech has a historically strong patent portfolio for its biologics, including multiple patents per drug.
- Market Impact: Successful infringement suit can delay biosimilar entry, preserving market share and revenues.
- Potential Damages: If infringement is proven, Sandoz could face injunctions, damages, or other remedies.
Risks and Opportunities
- Risks for Sandoz: Patent invalidation risks due to prior art or patent validity challenges.
- Opportunities for Sandoz: If patents are invalidated or not infringed, quick entry and market capture are possible.
- Legal Battles: Extended litigation duration could delay biosimilar launch and affect market dynamics.
Key Takeaways
- The case involves complex patent claims related to a biologic product.
- It reflects common legal tactics used in biologic patent enforcement.
- The outcome, potentially after years of litigation, could significantly influence biosimilar market access.
- Early procedural filings and arguments will shape the case trajectory.
- Both parties’ patent portfolios and market strategies are central to the dispute.
FAQs
What is the basis for Genentech’s patent infringement claim?
Genentech claims Sandoz’s biosimilar infringes patents covering the biologic’s composition, formulation, and therapeutic use, asserting unauthorized manufacturing and use of protected technology.
Has a trial date been set?
No. Patent litigation in district courts typically takes 18-36 months from filing to trial; the specific schedule for this case has not been publicized.
Could the patents be invalidated?
Yes. Patent validity challenges often occur through inter partes review at the Patent Trial and Appeal Board or judicial invalidation defenses during litigation.
How does this case compare to other biosimilar litigation?
It involves standard patent types (composition, formulation, use). Similar cases often focus on patent validity and infringement, with outcomes impacting biosimilar market entry timelines.
What are the potential market implications?
If Genentech prevails, biosimilar entry could be delayed by years. A favorable outcome for Sandoz could enable quicker market access, intensifying competition and potentially lowering prices.
References
[1] Kessler, T. (2021). Patent strategies in biosimilar competition. Biopharmaceutical Trends, 19(4), 232–245.
[2] Sung, C., & Kim, S. (2020). Patent litigation trends in biologics and biosimilars. Journal of Patent & Trademark Office Practice & Management, 37(2), 101–118.
Note: The specific procedural and case details are based on publicly available data and typical biosimilar patent litigation patterns with case reference to a 2023 filing; actual case developments could vary.
